Key Drivers
- High gross margin
- Strong free cashflow
- Elevated leverage
AIAI Summary
ALNY has transitioned into a product‑led, high‑margin commercial growth story where AMVUTTRA's U.S. ramp now drives valuation and near‑term cash generation, but that concentration makes upside highly contingent on sustaining diagnosis/take‑up and favorable reimbursement. Monitor AMVUTTRA gross‑to‑net/royalty trends, CMS diagnostic policy developments, and leverage reduction as the decisive catalysts that will validate—or quickly reverse—the current constructive thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Strong free cashflow
- •Elevated leverage
Alnylam combines exceptional gross margins and strong free cash flow with improving quarterly profitability, but faces material balance-sheet leverage, heavy R&D/opex and very rich valuation which heighten downside risk.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support holding
- •Resistance capped
Price has fallen roughly 7% over the last month to $312.17, creating a near-term downtrend with $312–$318 as short-term support and $332–$336 as resistance—break of $312 would likely open lower targets.
~7% decline from $336.19 to $312.17 over the last month indicating heightened downside risk
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Major Tenaya deal
- •Analyst buy consensus
Institutional accumulation and positive analyst sentiment amid investor outreach and a $1.13B Tenaya collaboration bolster Alnylam's growth narrative, though historical drawdowns underscore ongoing volatility.
The news strengthens Alnylam's medium-term upside case via partnerships and strong sales, but investors should expect continued price volatility given historical shock sensitivity
Similar Companies in Healthcare
Other companies in the same sector with AI ratings